30 results about "Serum plasma" patented technology

The invention discloses a preparation method of a CGRP detection kit and application of the CGRP detection kit in migraine diagnosis, and belongs to the technical field of biological medicine detection. According to the invention, alpha-CGRP polypeptide coupled KLH protein is subjected to efficient animal immunization, an antibody with good affinity is screened by using methods such as enzyme-linked immunosorbent assay, cross pairing analysis is carried out, and final antibody sequence information is obtained through sequencing. The paired monoclonal antibody screened by the invention has high sensitivity (KD value of 1nM), the limit of detection (LoD) can be as low as pg / mL level, a low-concentration CGRP sample can be effectively detected, the matrix effect of human serum / plasma can be effectively neutralized by an optimized sample diluent formula, and the repeatability is high (in-plate and inter-plate CV values of 1t and 10%). According to the invention, the kit prepared from the specific paired antibody is systematically and closely linked with the indication function of migraine for the first time, and a clinical diagnosis direction is provided.

The invention discloses a plasma or serum exosome separation method which comprises the following steps: firstly, coupling an antibody for resisting four transmembrane protein CD81 on the surface of an exosome by using a magnetic bead to form an immunomagnetic bead; pretreating a serum / plasma sample, enriching exosomes, co-incubating with the immunomagnetic beads, washing the magnetic beads after incubation capture is completed, and washing off uncombined impurities; after being captured, the exosome can be directly cracked, the magnetic beads are removed for downstream experiments, or the magnetic beads are eluted to obtain the complete exosome. The exosome affinity antibody is matched with the magnetic beads, the plasma / serum sample exosome is separated, the unique affinity separation technology not only can remove high-abundance protein in the serum / plasma sample, but also can eliminate other vesicles with similar membrane structures with the exosome, so that the purity of the separated exosome is far higher than that of the exosome obtained by other separation methods.

The application discloses a red blood cell alloantibody specificity analysis method, and aims at the defects in the prior art that a large amount of manual experience and subjective judgment are relied on to exclude positive antigens according to the results of non-agglutination of samples to be detected and cells, and scientific methods such as statistics are lacked to verify the reliability of detection results, and provides a red blood cell alloantibody specificity analysis method. According to the expression of red blood cell antigens of spectrum cells / anti-screen cells and the agglutination results of patient serum / plasma, the red blood cell alloantibody specificity is analyzed by using programmed analysis logic and statistical result analysis.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for NfL protein detection and application. The combination comprises monoclonal antibodies 9E1 and 10B4, and amino acid sequences of complementary determining regions of heavy chain and light chain variable regions of the monoclonal antibodies 9E1 and 10B4 are respectively shown as SEQ ID NO.1-12. The antibody combination can be used for constructing a double-antibody sandwich ELISA detection system and is especially suitable for being combined with a biotin-avidin signal amplification system to achieve high-sensitivity and high-specificity detection of the NfL protein, the detection sensitivity can reach 20 pg / mL, and the method is low in cost, easy and convenient to operate and suitable for quantitative analysis of the NfL protein in samples such as serum and plasma.

The invention relates to in vitro detection of biomarkers associated with drug-induced liver injury; belongs to the technical field of immunokits. The technical scheme provided by the invention is as follows: the soluble myeloid cell triggered receptor-1 is applied to preparation of a product for diagnosing the drug-induced liver injury as a biomarker. The invention discloses and proves that sTREM1 in serum or plasma can be used as a specific biomarker for diagnosing drug-induced liver injury (DILI), especially drug-induced liver fatty degeneration injury for the first time. The serum / plasma sTREM1 can detect abnormal rise in the extremely early stage (such as 7 days after medication) of the drug-induced liver injury, which is about 5-7 days earlier than that of the traditional marker ALT / AST, so that a key early intervention time window is provided for clinicians, and the liver injury can be prevented from further worsening.

The invention belongs to the technical field of biology, and discloses a sample diluent for ELISA (Enzyme-Linked Immunosorbent Assay), application of the sample diluent and a kit. The sample diluent comprises the following components: sodium chloride, sodium dodecyl sarcosinate and sodium caseinate, the mass ratio of the sodium chloride to the sodium dodecyl sarcosinate to the sodium caseinate is (1.6-6.4): (0.01-0.1): (0.5-2); according to the sample diluent, the synergistic effect of sodium chloride, sodium dodecyl sarcosinate and sodium caseinate with different concentrations is utilized, and matrix interference in animal serum / plasma can be remarkably reduced, so that the sensitivity and specificity of an ELISA kit are improved.

A method for the extraction and enrichment of Hepatitis C Virus (HCV) antigens by conjugating specific antibodies targeting Envelope 1, Envelope 2, NS3, and NS4 antigens to a temperature-responsive smart polymer (NIPAAm-Co-HIPAAm-Co-SAKIPAAm). The application also relates to a detection kit for HCV antigens, comprising the smart polymer conjugated to specific antibodies, colloidal gold nanoparticles conjugated to specific antibodies, and instructions for detecting HCV antigens in serum, plasma, or whole blood samples.

The application discloses application of a reagent for detecting ILA concentration in preparation of a product for predicting the curative effect of esophageal squamous cell carcinoma immunotherapy, a prediction method and equipment, and relates to the technical field of immunotherapy curative effect prediction. The reagent for detecting indole-3-lactic acid concentration is aimed at samples selected from serum, plasma, blood, tumor tissue or fecal samples. By establishing a prediction model for the curative effect of esophageal squamous cell carcinoma immunotherapy, the curative effect of immunotherapy on esophageal squamous cell carcinoma patients can be accurately predicted, valuable reference bases can be provided for clinicians, thus helping to formulate individualized immunotherapy strategies and improving the curative effect of immunotherapy.

The application provides a detection method of small molecule substances. The detection method comprises the following steps: mixing, incubating and mixing a sample, a diluent and a ligand, the small molecule substances in the sample are specifically combined with the ligand to form an immune complex, a complex antibody labeled with a signal generator is added, the complex antibody is specifically combined with a new conformation formed by the small molecule substances and the ligand to form a ternary immune complex, and the content of the ternary immune complex is detected; the molecular weight of the small molecule substance to be detected is less than 2000D; the diluent comprises a metal chelate and a buffer; the metal chelate comprises EDTA-2K or EDTA-2Na; the sample is a serum sample or a plasma sample, and the method solves the problem of detection difference between serum and plasma blood collection tube samples in the existing small molecule detection field.

The utility model provides a reagent card for whole blood separation liquid phase test, which comprises a card body, a separation cavity and an extraction cavity are arranged on the card body, a liquid outlet is arranged at the bottom of the separation cavity, and the liquid outlet is communicated with the extraction cavity; a filter membrane covering the liquid outlet is fixed in the separation cavity; a supercharging device is arranged in the separation cavity and used for increasing the air pressure in the separation cavity. A whole blood separation structure is arranged on the reagent card, when blood plasma or serum needs to be detected, collected whole blood is added into the separation cavity, the pressurizing device increases the air pressure in the separation cavity, the whole blood permeates the filtering membrane under the dual action of gravity and the air pressure to obtain the blood plasma or serum, the blood plasma or serum flows into the extraction cavity through the liquid outlet, and then the blood plasma or serum is extracted. A centrifugal device or a filtering device does not need to be additionally adopted for treating whole blood, and the operation convenience is improved.

The application discloses a platelet antibody detection and cross matching blocking chromatography kit and a detection method thereof, wherein the kit comprises a U-shaped microwell plate, a chromatography medium for separating platelet immune complexes from non-cell particle components under the action of centrifugal force, freeze-dried platelets, a platelet diluent, a platelet fluorescent staining solution comprising fluoresceinized platelet antibodies specifically labeled for platelets, biotin-labeled anti-human globulin for specifically binding with antibodies bound to the surface of the platelets, avidinized fluorescein for coupling with the biotin-labeled anti-human globulin through a biotin-avidin specific binding system, negative control serum / plasma and positive control serum / plasma. The application combines the blocking chromatography technology with a high-sensitivity flow immunofluorescence method to construct an efficient and accurate platelet antibody detection and cross matching system, which is high in specificity and sensitivity, simple in operation and stable in detection results.

The invention relates to the technical field of medical examination, and provides a detection tube for serum / plasma insufficiency samples, which comprises a blood collection tube, the top of the blood collection tube is fixedly connected with a tube opening convex edge, the top end of the blood collection tube is provided with a detection tube fitting, the detection tube fitting comprises a lower tube and an upper tube, the inner side of the upper tube is provided with a clamping groove in sliding fit with the tube opening convex edge, and the upper tube is provided with a clamping groove. An aluminum film adheres to the top of the upper-section pipe, a liquid pumping hose is fixedly connected to the bottom of the lower-section pipe, a one-way valve is fixedly connected to the liquid pumping hose, and a negative pressure piece which abuts against the pipe opening convex edge to pump out gas in the upper-section pipe to enable the upper-section pipe to generate negative pressure is arranged on the inner side of the clamping groove. A plurality of positioning pieces which are in sliding fit with the outer wall of the convex edge of the pipe orifice are arranged on the outer side of the upper-section pipe and are distributed around the upper-section pipe at equal angles. Through intelligent design and component optimization, the detection feasibility of the serum / plasma insufficiency sample is remarkably improved, and the progress of the medical examination technology is promoted.

This invention provides a material for detecting serum plasma anti-nicotinic acetylcholine receptor antibodies and its method of use. The material comprises HEK293T cells transfected with three recombinant expression plasmids: the first plasmid encodes a truncated AChR α subunit; the second plasmid is a polycistronic plasmid encoding a fusion protein composed of a truncated AChR β subunit, an AChR δ subunit, and rapsyn protein linked by a P2A peptide; and the third plasmid encodes a truncated AChR γ subunit or ε subunit. After co-transfection with PEI, the cells are cultured in fresh complete medium for 25-35 hours after 7-9 hours post-transfection, followed by fixation, blocking, and preservation. This invention, through a three-plasmid system and antigen truncation modification, reduces cytotoxicity while ensuring high expression of the functional pentamer, significantly improving detection sensitivity and reagent shelf life.

The invention discloses application of a reagent for detecting ILA concentration in preparation of a product for predicting esophageal squamous cell carcinoma immunotherapy curative effect, a prediction method and equipment, and relates to the technical field of immunotherapy curative effect prediction. A sample targeted by the reagent for detecting the concentration of indole-3-lactic acid is selected from serum, plasma, blood, tumor tissue or a fecal sample. By establishing the prediction model for the curative effect of the esophageal squamous cell carcinoma immunotherapy, the immunotherapy effect of a patient with the esophageal squamous cell carcinoma can be accurately predicted, and valuable reference bases can be provided for clinicians, so that making of personalized immunotherapy strategies is facilitated, and the effect of the immunotherapy is improved.

The present invention provides methods for using pre-operative bodily fluid as a source for a tumor reference genome. In some embodiments, the pre-operative bodily fluid is sequenced to identify a genomic variant specific to a tumor. In some embodiments, assays are performed to detect the presence of the genomic variant specific to a tumor identified in the pre-operative bodily fluid in surgical drain fluid. In some embodiments, the bodily fluids may be blood, urine, serum, plasma, saliva, sweat, milk, mucous, semen, vaginal or urethral secretions, cerebrospinal fluid, or surgical lavage fluid.

The invention discloses a novel amplification-free ultra-sensitive protein detection method and kit based on lanthanide MOF, and belongs to the technical field of protein detection and biosensing. According to the method, the lanthanide MOF material is specifically combined with the charge complementation of the target protein, and is combined with the signal amplification effect of the ssDNA of the labeled fluorophore and phosphate, so that the rapid quantitative detection of the low-abundance protein in the biological sample is realized. The kit comprises a lanthanide MOF material, ssDNA marked with fluorophores, a phosphate buffer solution, a target protein standard substance and the like. An enzyme or nucleic acid amplification step is not needed, the detection limit is as low as 1pg / mL, and compared with an ELISA method, the sensitivity gt is improved; the detection time is shortened to 1-2 h, the detection cost is only 1 / 16 of that of ELISA, and the kit is suitable for detection of protein markers in various biological samples such as serum, plasma and urine and can be widely applied to scenes such as early diagnosis of diseases, precise medical treatment and environmental monitoring.

The invention discloses a chemiluminescence immunoassay determination kit for detecting colloidal fibrillary acidic protein in a whole blood sample and a preparation method thereof, the determination kit comprises an R1 reagent which is streptavidin-coated magnetic particles, an R3 reagent which is an acridinium ester-labeled GFAP monoclonal antibody, and an R4 reagent which is a biotin-labeled GFAP monoclonal antibody, the reagent R3 and the reagent R4 are dissolved in a diluent, the diluent is a citric acid buffer solution containing a defoaming agent adapted to a whole blood sample system, and the defoaming agent is polydimethylsiloxane. A whole blood sample can be directly detected on a machine after being collected, separation treatment of serum and plasma is not needed, and the problems that in traditional serum and plasma sample detection, sample treatment time is long, and the detection turnover period is long can be effectively solved; meanwhile, the defoaming agent is added to prevent the formation of a bubble-protein compound, so that the detection precision of the reagent is remarkably improved.

The present application relates to a kind of extraction free DNA reagent based on suction filtration method, kit and extraction method.The kit contains reagent and adsorption column;The reagent includes lysing solution, proteinase K, protease solution, CarrierRNA, binding liquid, washing liquid and eluent;The adsorption column is the silica gel membrane adsorption column that can be used by suction filtration.The present application does not need centrifugal equipment, and the extraction and purification of DNA can be completed by suction filtration, with the characteristics of simple operation, low cost, high extraction rate, low safety risk, suitable for the extraction of free DNA in serum, plasma and other acellular samples.

The present invention provides methods for using pre-operative bodily fluid as a source for a tumor reference genome. In some embodiments, the pre-operative bodily fluid is sequenced to identify a genomic variant specific to a tumor. In some embodiments, assays are performed to detect the presence of the genomic variant specific to a tumor identified in the pre-operative bodily fluid in surgical drain fluid. In some embodiments, the bodily fluids may be blood, urine, serum, plasma, saliva, sweat, milk, mucous, semen, vaginal or urethral secretions, cerebrospinal fluid, or surgical lavage fluid.

The invention provides a homogeneous chemiluminescence determination kit and a quantitative determination method of pepsinogen I. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises a luminescence donor molecule coupled with a first antibody of pepsinogen I and a reaction buffer solution; and the R2 reagent comprises a light-emitting receptor molecule coupled with a pepsinogen I second antibody and a reaction buffer solution. A donor / receptor double-labeled antibody sandwich reaction is adopted, one-step incubation is achieved, solid-phase separation and washing are not needed, the process is remarkably simplified, and the detection time is shortened; by collecting the luminous intensity at 620 nm and 665 nm and quantifying the luminous intensity by a specific value signal, errors caused by sample turbidity, color and volume fluctuation and instrument drift can be effectively corrected; meanwhile, a protein blocking agent, a chelating agent and a heterophilic antibody blocking component are introduced into a reaction buffer system, interference of non-specific adsorption and rheumatoid factors / heterophilic antibodies is reduced, and adaptability to complex matrixes such as bile fluid and serum / plasma is enhanced.

A composition with exogenous mitochondria as active ingredients, and a use thereof and a cell repairing method therefor. The composition includes exogenous mitochondria and at least one pharmaceutically or cosmetically acceptable carrier. The composition may further include an adjuvant, and the adjuvant is selected from a group consisting of serum, plasma, complement and at least the above two ingredients. The exogenous mitochondria are obtained from cells by a centrifugal purification method.

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody combination for the detection of NfL protein and its application. The combination comprises monoclonal antibodies 9E1 and 10B4, whose complementary determinant amino acid sequences of the heavy and light chain variable regions are shown in SEQ ID NO. 1-12, respectively. The antibody combination can be used to construct a double-antibody sandwich ELISA detection system, particularly suitable for use with a biotin-avidin signal amplification system to achieve highly sensitive and specific detection of NfL protein, with a detection sensitivity of up to 20 pg / mL. This method is low-cost, simple to operate, and suitable for the quantitative analysis of NfL protein in serum, plasma, and other samples.

The invention provides a high-stability anti-ganglioside antibody detection membrane strip and a kit comprising the same, and belongs to the technical field of biological detection. The detection membrane strip comprises a carrier membrane and a ganglioside antigen coated on the surface of the carrier membrane, the surface of the carrier membrane is combined with the antigen through a thiol-Schiff base double-dynamic covalent network, and the network is composed of a Schiff base bond formed by a carrier membrane aldehyde group and an antigen sugar chain amino group, and a disulfide bond formed by a carrier membrane thiol group and an antigen lipid tail thiol group. The directional fixation of the antigen can be realized, and the dynamic repair capability is realized; a cascade anti-oxidation system is embedded into the network, so that the antigen stability is synergistically improved. The kit containing the membrane strip can be used for detecting the anti-ganglioside antibody in serum, plasma or cerebrospinal fluid, and solves the problems of short period of validity, large batch difference and the like caused by the fact that an existing detection membrane strip is easy to oxidize antigens and poor in coating stability.

The application discloses a kit for SND1 protein and application thereof, and comprises an enzyme-labeled plate coated with a monoclonal capture antibody X, ALP-labeled monoclonal detection antibody Y, SND1 standard, a substrate, the monoclonal capture antibody X and the detection antibody Y respectively comprising a heavy chain variable region and a light chain variable region shown in amino acid sequences as shown in SEQ ID NO. 1-14 and SEQ ID NO. 29-42, the heavy chain variable region comprising a heavy chain FR1, FR2, FR3, FR4 and a heavy chain CDR1, CDR2, CDR3, and the light chain variable region comprising a light chain FR1, FR2, FR3, FR4 and a light chain CDR1, CDR2, CDR3. The application prepares the monoclonal capture antibody X and the monoclonal detection antibody Y more suitable for early diagnosis of human serum and plasma SND1 tumor, and develops an early diagnosis kit capable of effectively detecting human serum and plasma SND1.

The application discloses a polypeptide and application thereof in preparation of an ICP auxiliary diagnosis kit. The polypeptide used for preparing an intrahepatic cholestasis of pregnancy auxiliary diagnosis kit has an amino acid sequence of QGAKIPKPEAS. The polypeptide is used as a detection target in preparation of an intrahepatic cholestasis of pregnancy serum / plasma auxiliary diagnosis reagent. The application also discloses application of a reagent for quantitatively detecting the polypeptide in preparation of an intrahepatic cholestasis of pregnancy serum / plasma auxiliary diagnosis reagent. The application finds that QGAKIPKPEAS is a small molecule peptide with high specificity and sensitivity and is highly related to the onset of ICP. The results of a multifactor logistic regression analysis show that QGAKIPKPEAS is significantly related to the onset of ICP, the ROC is as shown in the drawing, the AUC is 1.000, and the polypeptide can provide laboratory support for screening, diagnosis and treatment of ICP.

The invention relates to the technical field of detection kits, and provides an oxidized low-density lipoprotein colloidal gold immunochromatography detection kit. According to the kit for detecting the oxidized low-density lipoprotein, the oxidized low-density lipoprotein in serum, plasma and whole blood can be detected at the same time, treatment modes such as centrifugation and the like do not need to be carried out on a blood sample, and the detection time is greatly shortened; the kit has the advantages of high sensitivity, high repeatability, high specificity, wide linear range, low cost and the like, has the advantages of convenience in operation and detection while arrival of POCT (point-of-care testing) rapid diagnosis, and saves precious time for bedside detection, remote mountainous area and community detection and emergency treatment detection.

The invention provides a short-chain fatty acid serum substitute matrix and a preparation method thereof, and a detection method and a detection kit for simultaneously determining the content of various short-chain fatty acids in serum or plasma. The short-chain fatty acid serum substitute matrix comprises a stabilizer component and a diluent component, the stabilizer component is at least one of formic acid or phosphoric acid; the diluent comprises bovine serum albumin and a buffer solution. The serum substitute matrix disclosed by the invention relieves the technical problem that a real blank matrix is lacked during absolute quantification of short-chain fatty acids in the prior art, and realizes accurate quantification of various short-chain fatty acids in human serum and plasma. The invention makes it possible to use the blood SCFAs level as a biomarker for reflecting the whole body metabolic state, evaluating the risk of obesity, diabetes, cardiovascular diseases and other metabolic diseases, and monitoring the process and treatment effect of related diseases, and provides an important tool and basis for precise prevention, diagnosis and management of metabolic diseases.

This invention discloses a Mycoplasma pneumoniae antibody detection kit based on immunoturbidimetry, belonging to the field of clinical immunology testing. It includes solutions R1 and R2. Solution R1 is a dispersion of double-coupled latex microspheres coated with natural Mycoplasma pneumoniae antigens, and solution R2 is a sample diluent containing an enhancer. The test samples can be serum, plasma, or whole blood samples, and it is applicable to biochemical analyzers, protein analyzers, or combined blood cell and immunoturbidimetric analyzers. The kit prepared by this invention can be used on various instruments, has a wide range of detection targets, and can be coupled with other instruments to detect various clinically valuable blood indicators, further shortening the testing time. It solves the problems of poor accuracy, low efficiency, and limited application scenarios caused by the subjective interpretation of results, long processing time, and limited applicability of blood samples in existing technologies. It can effectively simplify the testing process and improve diagnostic efficiency.

A retrotransposable element based multiplexed qPCR assay to robustly quantitate and distinguish cell free DNA integrity and concentration in blood plasma and serum is described. The multiplexed system for characterizing cancer in humans includes a sample of serum, plasma, urine, or other biological fluid, the sample comprising cell free DNA, the cell free DNA comprising long and short retrotransposable element targets and an added internal positive control, the long and short targets being independent of each other, a distinctly labeled TaqMan probe corresponding to each target, a forward primer and a reverse primer corresponding to each target, a DNA standard for generating standard curves, a qPCR system for amplifying the targets and a qPCR data analysis system. The assay provides an accurate, minimally-invasive, rapid, high-throughput, and cost-effective method with the potential to complement or replace existing methods for detection, diagnosis, prognosis, treatment monitoring and / or surveillance of cancer, thereby improving patient outcomes.

The application belongs to the technical field of biology, and discloses a sample diluent for ELISA, application and kit thereof; the sample diluent comprises the following components: sodium chloride, sodium dodecyl sarcosinate and sodium caseinate; the mass ratio of the sodium chloride, the sodium dodecyl sarcosinate and the sodium caseinate is 1.6-6.4:0.01-0.1:0.5-2; the sample diluent utilizes the synergistic effect among sodium chloride, sodium dodecyl sarcosinate and sodium caseinate with different concentrations, can significantly reduce the matrix interference in animal serum / plasma, and thus improves the sensitivity and specificity of the ELISA kit.